Son B H, Choi J S, Lee J H
Department of General Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine [corrected] Seoul, Korea.
Pathology. 2005 Apr;37(2):131-6. doi: 10.1080/00313020500058144.
To investigate KAI1 and survivin expression in infiltrating ductal carcinomas, and to evaluate the relationship between clinicopathological factors and KAI1 and survivin expression levels in breast cancers.
KAI and survivin expression levels were measured in 62 patients, using immunohistochemical staining. Western blot analysis was performed on eight frozen cases. DNA ploidy was determined by flow cytometry. The results of the KAI1 expression analyses were as follows: in 14 cases (22.6%) levels were preserved (++), in 30 cases (48.4%) levels were reduced (+), in 18 cases (29.0%) no KAI1 expression was detected, so these were designated 'lost' (-). Results of assessments of survivin expression were as follows: six cases (9.7%) were strong positive (++), 28 cases (45.15%) were positive (+), and 28 cases (45.15%) were negative. Survivin (p=0.0009) and KAI1 (p=0.0091) expression levels were directly correlated with survival rate. However, no significant difference was determined to exist between survivin and KAI1 expression levels and the clinicopathological factors. DNA ploidy did not correlate with survivin and KAI1 expression levels and survival rate. Four different groups, according to their survivin and KAI1 expression levels, correlated with the clinical stage and survival rate.
KAI1 and survivin expression levels might be prognostic factors in breast cancers.
研究KAI1和生存素在浸润性导管癌中的表达情况，并评估乳腺癌临床病理因素与KAI1和生存素表达水平之间的关系。
采用免疫组织化学染色法检测62例患者的KAI和生存素表达水平。对8例冰冻病例进行蛋白质印迹分析。通过流式细胞术测定DNA倍体。KAI1表达分析结果如下：14例（22.6%）表达水平保持（++），30例（48.4%）表达水平降低（+），18例（29.0%）未检测到KAI1表达，因此这些被定为“缺失”（-）。生存素表达评估结果如下：6例（9.7%）为强阳性（++），28例（45.15%）为阳性（+），28例（45.15%）为阴性。生存素（p = 0.0009）和KAI1（p = 0.0091）表达水平与生存率直接相关。然而，生存素和KAI1表达水平与临床病理因素之间未发现显著差异。DNA倍体与生存素和KAI1表达水平及生存率无关。根据生存素和KAI1表达水平分为四个不同组，与临床分期和生存率相关。
KAI1和生存素表达水平可能是乳腺癌的预后因素。
